PaxMedica, Inc. (PXMD) acquired suramin research assets from Rediscovery Life Sciences, advancing its neurological disorder treatments. The assets, initially for acute kidney injury research, now support PaxMedica’s African Sleeping Sickness drug PAX-101 development. Following FDA discussions, this purchase aids the upcoming new drug application (NDA), keeping on schedule for 2024 manufacturing goals. CEO Howard Weisman hails the acquisition as pivotal for the expedited NDA process and combating Human African Sleeping Sickness.
PaxMedica, Inc. (Nasdaq: PXMD), a pioneering biopharmaceutical company specializing in cutting-edge treatments for neurological disorders, announced today the successful acquisition of certain suramin research assets from Rediscovery Life Sciences (RLS). These assets were previously dedicated to the study of suramin’s potential efficacy in treating acute kidney injury resulting from chronic kidney disease.
The newly acquired data from RLS will play a crucial role in bolstering PaxMedica’s ongoing efforts to support the submission for the approval of PAX-101, specifically for the treatment of African Sleeping Sickness caused by the Trypanosoma brucei rhodesiense parasite.
This strategic move follows PaxMedica’s recent Type B meeting with the FDA. The integration of the valuable data from Rediscovery Life Sciences will serve as a complementary component in the planned submission for the NDA, further solidifying the company’s progression toward this critical milestone. PaxMedica remains firmly on track to meet the CMC manufacturing production requirements for PAX-101 in the first half of 2024.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
In a recent statement, Howard Weisman, Chairman and CEO of PaxMedica, emphasized the significance of this acquisition, stating, “Acquiring the research assets from Rediscovery Life Sciences marks a significant leap forward in our journey to expedite the NDA submission process for PAX-101. This valuable addition of data will significantly contribute to our mission of delivering effective and life-saving treatments for Human African Sleeping Sickness.”
Source: Biospace